JP2016525529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525529A5 JP2016525529A5 JP2016528512A JP2016528512A JP2016525529A5 JP 2016525529 A5 JP2016525529 A5 JP 2016525529A5 JP 2016528512 A JP2016528512 A JP 2016528512A JP 2016528512 A JP2016528512 A JP 2016528512A JP 2016525529 A5 JP2016525529 A5 JP 2016525529A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- branched
- tetrahydroisoquinoline
- linear
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 51
- 239000002253 acid Substances 0.000 claims 39
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 33
- 150000003839 salts Chemical class 0.000 claims 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- -1 (morpholin-4-yl) methyl group Chemical group 0.000 claims 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 150000007513 acids Chemical class 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- AEZGJQRFXBCLEN-HKBQPEDESA-N CN(C(=O)c1cc(-c2cc3CCN(Cc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)C(O)=O)n(C)c1C)c1ccc(O)cc1 Chemical compound CN(C(=O)c1cc(-c2cc3CCN(Cc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)C(O)=O)n(C)c1C)c1ccc(O)cc1 AEZGJQRFXBCLEN-HKBQPEDESA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000006685 (C1-C6) polyhaloalkyl group Chemical group 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000003003 spiro group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 150000001768 cations Chemical class 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000005110 aryl thio group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 238000000926 separation method Methods 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000004185 ester group Chemical group 0.000 claims 3
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- UGBQHKNALULYFT-OAQYLSRUSA-N C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c(C)n1C)C(O)=O Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c(C)n1C)C(O)=O UGBQHKNALULYFT-OAQYLSRUSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 230000010933 acylation Effects 0.000 claims 2
- 238000005917 acylation reaction Methods 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 2
- 235000011180 diphosphates Nutrition 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 210000002816 gill Anatomy 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 2
- 239000000543 intermediate Substances 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000005897 peptide coupling reaction Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- 238000005694 sulfonylation reaction Methods 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- GNFLFHZJXXFDRA-UHFFFAOYSA-N 1,2-dimethylpyrrole Chemical compound CC1=CC=CN1C GNFLFHZJXXFDRA-UHFFFAOYSA-N 0.000 claims 1
- DRXOPQFEWDRGKT-UHFFFAOYSA-N 1,5-dimethylpyrrole-2-carbonitrile Chemical compound CC1=CC=C(C#N)N1C DRXOPQFEWDRGKT-UHFFFAOYSA-N 0.000 claims 1
- ZVOCBNCKNQJAFL-UHFFFAOYSA-N 1-methylpyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2N(C)C=CC2=C1 ZVOCBNCKNQJAFL-UHFFFAOYSA-N 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- ZAIVVAGEIPDXTO-WJOKGBTCSA-N 3-[2-[2-[4-[(dimethylamino)methyl]phenyl]acetyl]-7-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-3,4-dihydro-1H-isoquinolin-6-yl]-N-(4-hydroxyphenyl)-N-methyl-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c2CCCCn12)C(=O)Cc1ccc(CN(C)C)cc1 ZAIVVAGEIPDXTO-WJOKGBTCSA-N 0.000 claims 1
- JZAUOSYMVYCYDR-JGCGQSQUSA-N 3-[2-[2-[4-[2-(dimethylamino)ethoxy]phenyl]acetyl]-7-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-3,4-dihydro-1H-isoquinolin-6-yl]-N-(4-hydroxyphenyl)-N-methyl-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c2CCCCn12)C(=O)Cc1ccc(OCCN(C)C)cc1 JZAUOSYMVYCYDR-JGCGQSQUSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 1
- QYASHELNMUPRKF-UHFFFAOYSA-N 5,6,7,8-tetrahydroindolizine Chemical compound C1CCCN2C=CC=C21 QYASHELNMUPRKF-UHFFFAOYSA-N 0.000 claims 1
- RFKIFIKTFDVAPX-XIFFEERXSA-N 6-[4-[(4-hydroxyphenyl)-propylcarbamoyl]-1,5-dimethylpyrrol-2-yl]-7-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid Chemical compound CCCN(C(=O)c1cc(-c2cc3CCN(Cc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)C(O)=O)n(C)c1C)c1ccc(O)cc1 RFKIFIKTFDVAPX-XIFFEERXSA-N 0.000 claims 1
- ANESXWDARVOCOY-UMSFTDKQSA-N 6-[4-[butyl-(4-hydroxyphenyl)carbamoyl]-1,5-dimethylpyrrol-2-yl]-7-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid Chemical compound CCCCN(C(=O)c1cc(-c2cc3CCN(Cc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)C(O)=O)n(C)c1C)c1ccc(O)cc1 ANESXWDARVOCOY-UMSFTDKQSA-N 0.000 claims 1
- BCEQFIZLMALFBJ-MGBGTMOVSA-N N-(4-hydroxyphenyl)-N-methyl-3-[7-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-[2-[3-(4-methylpiperazin-1-yl)phenyl]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c2CCCCn12)C(=O)Cc1cccc(c1)N1CCN(C)CC1 BCEQFIZLMALFBJ-MGBGTMOVSA-N 0.000 claims 1
- WESHRFBTAOBSPA-MGBGTMOVSA-N N-(4-hydroxyphenyl)-N-methyl-3-[7-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-[2-[4-(4-methylpiperazin-1-yl)phenyl]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c2CCCCn12)C(=O)Cc1ccc(cc1)N1CCN(C)CC1 WESHRFBTAOBSPA-MGBGTMOVSA-N 0.000 claims 1
- LSDBELUKOABOBK-MGBGTMOVSA-N N-(4-hydroxyphenyl)-N-methyl-3-[7-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-[2-[4-(morpholin-4-ylmethyl)phenyl]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c2CCCCn12)C(=O)Cc1ccc(CN2CCOCC2)cc1 LSDBELUKOABOBK-MGBGTMOVSA-N 0.000 claims 1
- MLDJYPAJCQNMQN-UUWRZZSWSA-N N-(4-hydroxyphenyl)-N-methyl-3-[7-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-[2-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2CN(CCc2cc1-c1cc(C(=O)N(C)c2ccc(O)cc2)c2CCCCn12)C(=O)Cc1ccc(CN2CCN(C)CC2)cc1 MLDJYPAJCQNMQN-UUWRZZSWSA-N 0.000 claims 1
- UCZOGTLOGCSHIN-RWYGWLOXSA-N N-butyl-N-(4-hydroxyphenyl)-1,2-dimethyl-5-[7-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-(2-phenylacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]pyrrole-3-carboxamide Chemical compound C(CCC)N(C(=O)C1=C(N(C(=C1)C=1C=C2CCN(CC2=CC=1C(=O)N1CC2=CC=CC=C2C[C@H]1CN1CCOCC1)C(CC1=CC=CC=C1)=O)C)C)C1=CC=C(C=C1)O UCZOGTLOGCSHIN-RWYGWLOXSA-N 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 150000001263 acyl chlorides Chemical class 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 231100000024 genotoxic Toxicity 0.000 claims 1
- 230000001738 genotoxic effect Effects 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR13/57276 | 2013-07-23 | ||
| FR1357276A FR3008977A1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/EP2014/065764 WO2015011164A1 (en) | 2013-07-23 | 2014-07-22 | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525529A JP2016525529A (ja) | 2016-08-25 |
| JP2016525529A5 true JP2016525529A5 (enExample) | 2017-08-31 |
| JP6395829B2 JP6395829B2 (ja) | 2018-09-26 |
Family
ID=49911606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528512A Active JP6395829B2 (ja) | 2013-07-23 | 2014-07-22 | 新規イソインドリン又はイソキノリン化合物、それらの調製のためのプロセス及びそれらを含有する医薬組成物 |
Country Status (49)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3445762B1 (en) | 2016-04-20 | 2023-09-13 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
| MA53014A (fr) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics Inc | Composés améliorant l'activité du protéasome |
| WO2021093795A1 (zh) * | 2019-11-15 | 2021-05-20 | 武汉朗来科技发展有限公司 | 一种rock抑制剂及其制备方法和用途 |
| CN112010796B (zh) * | 2020-09-17 | 2022-04-22 | 浙江大学 | 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法 |
| EP4294513A1 (en) | 2021-02-19 | 2023-12-27 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
| CA3251659A1 (en) | 2022-02-24 | 2023-08-31 | Servier Lab | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| JPWO2024204846A1 (enExample) * | 2023-03-31 | 2024-10-03 | ||
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| WO2004096774A1 (en) * | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
| US20050070570A1 (en) | 2003-06-18 | 2005-03-31 | 4Sc Ag | Novel potassium channels modulators |
| CN101039662A (zh) * | 2004-08-20 | 2007-09-19 | 密执安州立大学董事会 | 抗－细胞凋亡bcl－2家族成员的小分子抑制剂及其应用 |
| CA2577752A1 (en) * | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| WO2006087309A1 (en) * | 2005-02-15 | 2006-08-24 | Novo Nordisk A/S | 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters |
| US8445679B2 (en) | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
| CA2707445A1 (en) | 2007-11-30 | 2009-06-11 | Biota Scientific Management Pty Ltd | Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| WO2009102463A2 (en) | 2008-02-14 | 2009-08-20 | Connor Reynolds | Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same |
| EP2714681B1 (en) * | 2011-05-25 | 2015-06-24 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| EA201491264A1 (ru) * | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
| WO2013100890A1 (en) | 2011-12-27 | 2013-07-04 | Intel Corporation | Methods and systems to control power gates during an active state of a gated domain based on load conditions of the gated domain |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357276A patent/FR3008977A1/fr not_active Withdrawn
-
2014
- 2014-07-13 JO JOP/2014/0223A patent/JO3457B1/ar active
- 2014-07-15 UY UY0001035664A patent/UY35664A/es active IP Right Grant
- 2014-07-22 US US14/905,985 patent/US9809574B2/en active Active
- 2014-07-22 MX MX2016000904A patent/MX365373B/es active IP Right Grant
- 2014-07-22 DK DK14741648.1T patent/DK3024826T3/en active
- 2014-07-22 CN CN201480042422.3A patent/CN105431422B/zh active Active
- 2014-07-22 PL PL14741648T patent/PL3024826T3/pl unknown
- 2014-07-22 SI SI201431038T patent/SI3024826T1/sl unknown
- 2014-07-22 PE PE2016000023A patent/PE20160241A1/es unknown
- 2014-07-22 TW TW103125161A patent/TWI560184B/zh not_active IP Right Cessation
- 2014-07-22 CU CUP2016000010A patent/CU24352B1/xx unknown
- 2014-07-22 NZ NZ716155A patent/NZ716155A/en unknown
- 2014-07-22 HK HK16106761.6A patent/HK1218754A1/zh unknown
- 2014-07-22 LT LTEP14741648.1T patent/LT3024826T/lt unknown
- 2014-07-22 JP JP2016528512A patent/JP6395829B2/ja active Active
- 2014-07-22 CA CA2919572A patent/CA2919572C/en active Active
- 2014-07-22 WO PCT/EP2014/065764 patent/WO2015011164A1/en not_active Ceased
- 2014-07-22 RS RS20190150A patent/RS58344B1/sr unknown
- 2014-07-22 PT PT14741648T patent/PT3024826T/pt unknown
- 2014-07-22 EP EP14741648.1A patent/EP3024826B1/en active Active
- 2014-07-22 TN TN2016000003A patent/TN2016000003A1/en unknown
- 2014-07-22 CN CN201811358313.9A patent/CN109456324B/zh active Active
- 2014-07-22 TR TR2018/19155T patent/TR201819155T4/tr unknown
- 2014-07-22 RU RU2016106003A patent/RU2689305C2/ru active
- 2014-07-22 AU AU2014295101A patent/AU2014295101B2/en active Active
- 2014-07-22 BR BR112016001080-9A patent/BR112016001080B1/pt active IP Right Grant
- 2014-07-22 MA MA38801A patent/MA38801B1/fr unknown
- 2014-07-22 ES ES14741648T patent/ES2711371T3/es active Active
- 2014-07-22 MY MYPI2016700106A patent/MY193619A/en unknown
- 2014-07-22 GE GEAP201414063A patent/GEP20207070B/en unknown
- 2014-07-22 KR KR1020167004570A patent/KR102008431B1/ko active Active
- 2014-07-22 HR HRP20190277TT patent/HRP20190277T1/hr unknown
- 2014-07-22 UA UAA201601395A patent/UA117490C2/uk unknown
- 2014-07-22 MD MDA20160018A patent/MD4793C1/ro not_active IP Right Cessation
- 2014-07-22 SG SG11201600205XA patent/SG11201600205XA/en unknown
- 2014-07-22 EA EA201600122A patent/EA032301B1/ru unknown
- 2014-07-22 AR ARP140102713A patent/AR097009A1/es active IP Right Grant
- 2014-07-22 ME MEP-2019-35A patent/ME03346B/me unknown
- 2014-07-22 AP AP2016008989A patent/AP2016008989A0/xx unknown
- 2014-07-22 HU HUE14741648A patent/HUE041443T2/hu unknown
-
2016
- 2016-01-03 IL IL243449A patent/IL243449A0/en active IP Right Grant
- 2016-01-06 PH PH12016500034A patent/PH12016500034B1/en unknown
- 2016-01-11 DO DO2016000009A patent/DOP2016000009A/es unknown
- 2016-01-11 ZA ZA2016/00198A patent/ZA201600198B/en unknown
- 2016-01-15 CR CR20160030A patent/CR20160030A/es unknown
- 2016-01-20 CL CL2016000148A patent/CL2016000148A1/es unknown
- 2016-01-21 NI NI201600016A patent/NI201600016A/es unknown
- 2016-01-21 SA SA516370439A patent/SA516370439B1/ar unknown
-
2017
- 2017-09-14 US US15/704,330 patent/US10689364B2/en active Active
-
2019
- 2019-02-11 CY CY20191100175T patent/CY1121247T1/el unknown
-
2020
- 2020-05-04 US US16/865,799 patent/US11028070B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525529A5 (enExample) | ||
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| AU2018360853B2 (en) | Modulators of the integrated stress pathway | |
| RU2016106003A (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP6529085B2 (ja) | 複素環化合物 | |
| KR20250029954A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| JP2024517772A (ja) | 置換された２－（２，６－ジオキソピペリジン－３－イル）－５－（１－ピペリジン－４－イル）イソインドリン－１，３－ジオン誘導体及びその使用 | |
| JP2019525962A (ja) | ケモカイン受容体調節剤及びそれの使用 | |
| JP2021501779A (ja) | 統合的ストレス経路の調節剤 | |
| KR20110031475A (ko) | 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법 | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| CA3056833A1 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| BR102014017997A2 (pt) | compostos do tipo fosfato, um processo para sua preparação e composições farmacêuticas contendo os mesmos | |
| JP2016531108A5 (enExample) | ||
| JP5608098B2 (ja) | キナーゼ阻害薬としてのピラゾロピリジン | |
| RU2016106002A (ru) | Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP2020515546A (ja) | Ｍｄｍ２−ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス | |
| ES2742078T3 (es) | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa | |
| JP6837072B2 (ja) | ６，７−ジヒドロ−５Ｈ−ピラゾロ［５，１−ｂ］［１，３］オキサジン−２−カルボキサミド化合物 | |
| JP6976248B2 (ja) | （ｒ）−１−（４−（６−（２−（４−（３，３−ジフルオロシクロブトキシ）−６−メチルピリジン−２−イル）アセトアミド）ピリダジン−３−イル）−２−フルオロブチル）−ｎ−メチル−１ｈ−１，２，３−トリアゾール−４−カルボキサミドの塩形態および多形体 | |
| JP7050761B2 (ja) | ８－（アゼチジン－１－イル）－［１，２，４］トリアゾロ［１，５－ａ］ピリジニル化合物、組成物及びその使用方法 | |
| ES2782113T3 (es) | Compuestos de quinolina fusionados como inhibidores de PI3K/mTor | |
| WO2016115869A1 (zh) | Flt3激酶的新型抑制剂及其用途 | |
| CN107848971B (zh) | 杂环化合物 |